Clinical Evidence Supports Medical Necessity of Annular Repair Using Barricaid

Barricaid, the only FDA approved device proven to reduce disc reherniation, has reached
another significant milestone. On June 23, 2021, Hayes published a comprehensive Health
Technology Assessment (HTA) which complements the previously published positive HTA
by ECRI. The Hayes assessment confirms that the Barricaid technology is founded upon a
substantial body of clinical and economic evidence.

Implantation of Barricaid for large annular defects significantly reduces the risk of recurrent
lumbar disc herniation and subsequent reoperation. This treatment option uniquely balances
the concerns of recurrent herniation and disc preservation within the large defect population,
holding the potential to improve surgical outcomes and quality of life while reducing payor
expenses.

If Barricaid is right for you, we can help.

Sign up to receive future updates and information on the Barricaid procedure.
  • This field is for validation purposes and should be left unchanged.